Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if diagnosed early.

SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.

An experimental drug has successfully slowed the progress of amyotrophic lateral sclerosis in a phase 2 study, its developer announced on Tuesday. Participants taking AMX0035, designed to reduce ...

Researchers in Germany say combining two blood biomarkers may make the diagnosis of ALS more accurate and help predict disease progression.

The onset of amyotrophic lateral sclerosis (ALS) is more common in adults over the age of 40 years. However, ALS may also occur in people in their 20s or 30s. ALS is a rare progressive ...

Degradation of motor neurons, conceptual computer illustration. Motor neuron diseases are a group of neurodegenerative disorders including amyotrophic lateral sclerosis, progressive bulbar palsy and ...

ALS is a progressive disease, meaning it worsens over time. Although there is no cure for ALS, medications and therapies are available to help manage the symptoms, slow the disease course, and prolong ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...